TipRanks
Elevance Health (MX:ELV)
:ELV
Mexico Market
ELV
Elevance Health
RESEARCH TOOLSreports

Elevance Health (ELV) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ELV Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
9 Buy
5 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$8,857.68
▲(37.35% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $8,857.68 with a high forecast of $9,704.05 and a low forecast of $7,533.17. The average price target represents a 37.35% change from the last price of $6,449.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5146":"$5,146","9705":"$9,705","6285.75":"$6,285.8","7425.5":"$7,425.5","8565.25":"$8,565.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9704.0541787,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8857.679104723078,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7533.1663414,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5146,6285.75,7425.5,8565.25,9705],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7168.41,7363.4595522076925,7558.509104415384,7753.558656623077,7948.608208830769,8143.657761038461,8338.707313246154,8533.756865453846,8728.806417661539,8923.855969869232,9118.905522076922,9313.955074284615,9509.004626492308,{"y":9704.0541787,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7168.41,7298.35377728639,7428.297554572781,7558.241331859172,7688.185109145563,7818.128886431953,7948.072663718343,8078.016441004735,8207.960218291126,8337.903995577515,8467.847772863906,8597.791550150298,8727.735327436687,{"y":8857.679104723078,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7168.41,7196.468180107692,7224.526360215385,7252.584540323077,7280.642720430769,7308.700900538462,7336.759080646154,7364.817260753846,7392.875440861539,7420.933620969231,7448.991801076923,7477.049981184616,7505.108161292308,{"y":7533.1663414,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5922.852,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6187.614,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5655.196,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5911.459,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5951.97,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5540.853,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5147.244,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5478.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6714.228,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7114.521,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6422.335,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6422.335,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7168.41,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$9,704Average Price Target$8,858Lowest Price Target$7,533
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on MX:ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$8,776.32→$9,128.86
Buy
41.55%
Upside
Assigned
10/27/26
Stephen Baxter Boosts Elevance Health Price Target to $492 on Strong Core Earnings and Favorable Medicare Outlook
Mizuho Securities Analyst forecast on MX:ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$8,720.66→$9,091.75
Buy
40.98%
Upside
Reiterated
10/23/26
Elevance Health price target raised to $490 from $470 at MizuhoElevance Health price target raised to $490 from $470 at Mizuho
TD Cowen Analyst forecast on MX:ELV
Ryan Langston
TD Cowen
TD Cowen
$8,627.89→$9,184.53
Buy
42.42%
Upside
Reiterated
10/23/26
TD Cowen Reaffirms Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on MX:ELV
David S Macdonald
Truist Financial
Truist Financial
$8,813.43→$9,277.3
Buy
43.86%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $500 from $475 at TruistElevance Health price target raised to $500 from $475 at Truist
Morgan Stanley Analyst forecast on MX:ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$7,496.06→$8,331.01
Hold
29.18%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $449 from $404 at Morgan StanleyElevance Health price target raised to $449 from $404 at Morgan Stanley
UBS Analyst forecast on MX:ELV
A.J. Rice
UBS
UBS
$8,535.11→$9,704.05
Buy
50.47%
Upside
Assigned
10/22/26
Elevance Health price target raised to $523 from $460 at UBSElevance Health price target raised to $523 from $460 at UBS
Goldman Sachs Analyst forecast on MX:ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$7,329.07→$8,368.12
Hold
29.76%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $451 from $395 at Goldman SachsElevance Health price target raised to $451 from $395 at Goldman Sachs
Bank of America Securities Analyst forecast on MX:ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$9,277.3
Buy
43.86%
Upside
Assigned
10/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB), Elevance Health (NYSE: ELV) and Myriad Genetics (NASDAQ: MYGN)
Robert W. Baird Analyst forecast on MX:ELV
Michael Ha
Robert W. Baird
Robert W. Baird
$7,291.96→$7,533.17
Hold
16.81%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $406 from $393 at BairdElevance Health price target raised to $406 from $393 at Baird
Barclays Analyst forecast on MX:ELV
Andrew Mok CFA
Barclays
Barclays
$8,702.11→$8,757.77
Buy
35.80%
Upside
Reiterated
10/22/26
Barclays Keeps Their Buy Rating on Elevance Health (ELV)
RBC Capital Analyst forecast on MX:ELV
Ben Hendrix
RBC Capital
RBC Capital
$7,867.15→$8,442.34
Hold
30.91%
Upside
Reiterated
10/21/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)
Guggenheim Analyst forecast on MX:ELV
Jason Cassorla
Guggenheim
Guggenheim
$8,535.11→$8,998.98
Buy
39.54%
Upside
Reiterated
10/21/26
Elevance Health price target raised to $485 from $460 at GuggenheimElevance Health price target raised to $485 from $460 at Guggenheim
Bernstein Analyst forecast on MX:ELV
Lance Wilkes
Bernstein
Bernstein
$9,054.64
Buy
40.40%
Upside
Reiterated
10/05/26
Bernstein Reaffirms Their Buy Rating on Elevance Health (ELV)
Argus Research Analyst forecast on MX:ELV
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Leerink Partners Analyst forecast on MX:ELV
Whit Mayo
Leerink Partners
Leerink Partners
$6,753.87→$7,329.07
Hold
13.65%
Upside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on MX:ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$8,776.32→$9,128.86
Buy
41.55%
Upside
Assigned
10/27/26
Stephen Baxter Boosts Elevance Health Price Target to $492 on Strong Core Earnings and Favorable Medicare Outlook
Mizuho Securities Analyst forecast on MX:ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$8,720.66→$9,091.75
Buy
40.98%
Upside
Reiterated
10/23/26
Elevance Health price target raised to $490 from $470 at MizuhoElevance Health price target raised to $490 from $470 at Mizuho
TD Cowen Analyst forecast on MX:ELV
Ryan Langston
TD Cowen
TD Cowen
$8,627.89→$9,184.53
Buy
42.42%
Upside
Reiterated
10/23/26
TD Cowen Reaffirms Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on MX:ELV
David S Macdonald
Truist Financial
Truist Financial
$8,813.43→$9,277.3
Buy
43.86%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $500 from $475 at TruistElevance Health price target raised to $500 from $475 at Truist
Morgan Stanley Analyst forecast on MX:ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$7,496.06→$8,331.01
Hold
29.18%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $449 from $404 at Morgan StanleyElevance Health price target raised to $449 from $404 at Morgan Stanley
UBS Analyst forecast on MX:ELV
A.J. Rice
UBS
UBS
$8,535.11→$9,704.05
Buy
50.47%
Upside
Assigned
10/22/26
Elevance Health price target raised to $523 from $460 at UBSElevance Health price target raised to $523 from $460 at UBS
Goldman Sachs Analyst forecast on MX:ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$7,329.07→$8,368.12
Hold
29.76%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $451 from $395 at Goldman SachsElevance Health price target raised to $451 from $395 at Goldman Sachs
Bank of America Securities Analyst forecast on MX:ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$9,277.3
Buy
43.86%
Upside
Assigned
10/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB), Elevance Health (NYSE: ELV) and Myriad Genetics (NASDAQ: MYGN)
Robert W. Baird Analyst forecast on MX:ELV
Michael Ha
Robert W. Baird
Robert W. Baird
$7,291.96→$7,533.17
Hold
16.81%
Upside
Reiterated
10/22/26
Elevance Health price target raised to $406 from $393 at BairdElevance Health price target raised to $406 from $393 at Baird
Barclays Analyst forecast on MX:ELV
Andrew Mok CFA
Barclays
Barclays
$8,702.11→$8,757.77
Buy
35.80%
Upside
Reiterated
10/22/26
Barclays Keeps Their Buy Rating on Elevance Health (ELV)
RBC Capital Analyst forecast on MX:ELV
Ben Hendrix
RBC Capital
RBC Capital
$7,867.15→$8,442.34
Hold
30.91%
Upside
Reiterated
10/21/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)
Guggenheim Analyst forecast on MX:ELV
Jason Cassorla
Guggenheim
Guggenheim
$8,535.11→$8,998.98
Buy
39.54%
Upside
Reiterated
10/21/26
Elevance Health price target raised to $485 from $460 at GuggenheimElevance Health price target raised to $485 from $460 at Guggenheim
Bernstein Analyst forecast on MX:ELV
Lance Wilkes
Bernstein
Bernstein
$9,054.64
Buy
40.40%
Upside
Reiterated
10/05/26
Bernstein Reaffirms Their Buy Rating on Elevance Health (ELV)
Argus Research Analyst forecast on MX:ELV
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Leerink Partners Analyst forecast on MX:ELV
Whit Mayo
Leerink Partners
Leerink Partners
$6,753.87→$7,329.07
Hold
13.65%
Upside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
Andrew Mok CFABarclays
Success Rate
13/19 ratings generated profit
68%
Average Return
+1.35%
Copying Andrew Mok CFA's trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +1.35% per trade.
1 Year
George HillDeutsche Bank
Success Rate
14/18 ratings generated profit
78%
Average Return
+16.06%
Copying George Hill's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +16.06% per trade.
2 Years
A.J. RiceUBS
Success Rate
28/31 ratings generated profit
90%
Average Return
+37.96%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 90.32% of your transactions generating a profit, with an average return of +37.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
30
27
21
20
20
Hold
9
9
9
8
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
36
30
28
26
In the current month, ELV has received 20 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 8,857.68.
Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $38.88 with a range of $30.64 to $60.16. The previous quarter’s EPS was $130.60. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ELV is $38.88 with a range of $30.64 to $60.16. The previous quarter’s EPS was $130.60. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $922.53B with a range of $878.54B to $971.54B. The previous quarter’s sales results were $960.88B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s sales forecast for ELV is $922.53B with a range of $878.54B to $971.54B. The previous quarter’s sales results were $960.88B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is MX:ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 8,857.68.
    What is MX:ELV’s upside potential, based on the analysts’ average price target?
    Elevance Health has 37.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Elevance Health a Buy, Sell or Hold?
          Elevance Health has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Elevance Health’s share price target?
            The average share price target for Elevance Health is 8,857.68. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $9,704.05 ,and the lowest forecast is $7,533.17. The average share price target represents 37.35% Increase from the current price of $6,449.
              What do analysts say about Elevance Health?
              Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of Elevance Health?
                To buy shares of MX:ELV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.